{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T07:13:31Z","timestamp":1781939611349,"version":"3.54.5"},"reference-count":26,"publisher":"The Journal of Rheumatology","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"accepted":{"date-parts":[[2025,8,26]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Anti-integrin \u03b1v\u03b26 autoantibodies (anti-\u03b1v\u03b26) have recently been described as informative biomarkers for ulcerative colitis (UC), demonstrating a high sensitivity and specificity compared to patients without inflammatory bowel disease (IBD). Given the association between axial spondyloarthritis (axSpA) and IBD, we sought to evaluate the potential of anti-\u03b1v\u03b26 as a biomarker in axSpA patients with or without concurrent IBD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using an established ELISA protocol, we measured anti-\u03b1v\u03b26 levels in sera of patients with (1) axSpA and UC, (2) axSpA and Crohn disease (CD), (3) axSpA alone, and (4) healthy controls (HCs). Anti-\u03b1v\u03b26 absorbance values were compared between patient groups and clinical variables were compared with anti-\u03b1v\u03b26 positivity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eighteen patients with axSpA and UC, 29 with CD, 48 with axSpA alone, and 48 HCs were included. Patients with axSpA and UC showed a significant increase in mean absorbance and anti-\u03b1v\u03b26 positivity rate compared with axSpA alone. For the diagnosis of UC among patients with axSpA, anti-\u03b1v\u03b26 had a sensitivity of 55.6% and specificity of 89.6%, and receiver-operating characteristic analysis yielded an area under the curve value of 0.83. Anti-\u03b1v\u03b26 positivity was associated with a family history of IBD in patients with axSpA and UC. Surprisingly, anti-\u03b1v\u03b26\u2013positive patients had decreased mean C-reactive protein and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) scores compared with anti-\u03b1v\u03b26\u2013negative patients. Examining serial samples, we observed that 3 of 10 anti-\u03b1v\u03b26\u2013positive patients became anti-\u03b1v\u03b26\u2013negative, whereas anti-\u03b1v\u03b26\u2013negative to anti-\u03b1v\u03b26\u2013positive transitions were not observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Anti-\u03b1v\u03b26 positivity demonstrated potential as a diagnostic test for UC in patients with axSpA, particularly those with a family history of IBD. To our knowledge, this is the first study to date examining anti-\u03b1v\u03b26 in axSpA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3899\/jrheum.2024-1296","type":"journal-article","created":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T12:25:14Z","timestamp":1757939114000},"page":"25-32","source":"Crossref","is-referenced-by-count":1,"title":["Anti-Integrin \u03b1v\u03b26 Autoantibodies as a Biomarker for Ulcerative Colitis in Patients With Axial Spondyloarthritis"],"prefix":"10.3899","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-8013-097X","authenticated-orcid":false,"given":"Enoch","family":"Yau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Chim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6956-8687","authenticated-orcid":false,"given":"Melissa","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4750-1422","authenticated-orcid":false,"given":"Robert D.","family":"Inman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2025,9,15]]},"reference":[{"key":"2026010105291313000_53.1.25.1","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00281-021-00845-0","article-title":"The gut-joint axis in spondyloarthritis: immunological, microbial, and clinical insights","volume":"43","author":"Qaiyum","year":"2021","journal-title":"Semin Immunopathol"},{"key":"2026010105291313000_53.1.25.2","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3528"},{"key":"2026010105291313000_53.1.25.3","doi-asserted-by":"crossref","first-page":"932393","DOI":"10.3389\/fimmu.2022.932393","article-title":"Cytokine competent gut-joint migratory T cells contribute to inflammation in the joint","volume":"13","author":"Lefferts","year":"2022","journal-title":"Front Immunol"},{"key":"2026010105291313000_53.1.25.4","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2018.27"},{"key":"2026010105291313000_53.1.25.5","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2009.727"},{"key":"2026010105291313000_53.1.25.6","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1053\/j.gastro.2021.02.019","article-title":"Identification of an anti-integrin \u03b1v\u03b26 autoantibody in patients with ulcerative colitis","volume":"160","author":"Kuwada","year":"2021","journal-title":"Gastroenterology"},{"key":"2026010105291313000_53.1.25.7","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1053\/j.gastro.2022.06.026","article-title":"Anti-integrin \u03b1v\u03b26 antibody as a diagnostic marker for pediatric patients with ulcerative colitis","volume":"163","author":"Muramoto","year":"2022","journal-title":"Gastroenterology"},{"key":"2026010105291313000_53.1.25.8","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.3390\/jcm11071881","article-title":"Measurement of serum IgG anti-integrin \u03b1v\u03b26 autoantibodies is a promising tool in the diagnosis of ulcerative colitis","volume":"11","author":"Rydell","year":"2022","journal-title":"J Clin Med"},{"key":"2026010105291313000_53.1.25.9","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2022.12.042"},{"key":"2026010105291313000_53.1.25.10","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.dld.2023.06.024","article-title":"Diagnostic value of anti-integrin \u03b1v\u03b26 antibodies in ulcerative colitis","volume":"56","author":"Marafini","year":"2024","journal-title":"Dig Liver Dis"},{"key":"2026010105291313000_53.1.25.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2018.04.013"},{"key":"2026010105291313000_53.1.25.12","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1038\/s41416-024-02647-1","article-title":"Anti-integrin \u03b1v\u03b26 autoantibodies are a potential biomarker for ulcerative colitis-like immune checkpoint inhibitor-induced colitis","volume":"130","author":"Yokode","year":"2024","journal-title":"Br J Cancer"},{"key":"2026010105291313000_53.1.25.13","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1007\/s00535-023-02006-6","article-title":"Anti-integrin \u03b1v\u03b26 autoantibodies in patients with primary sclerosing cholangitis","volume":"58","author":"Yoshida","year":"2023","journal-title":"J Gastroenterol"},{"key":"2026010105291313000_53.1.25.14","doi-asserted-by":"publisher","DOI":"10.1186\/ar4350"},{"key":"2026010105291313000_53.1.25.15","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-032414-112110"},{"key":"2026010105291313000_53.1.25.16","doi-asserted-by":"crossref","first-page":"1387516","DOI":"10.3389\/fimmu.2024.1387516","article-title":"Anti-integrin \u03b1v\u03b26 antibody in Takayasu arteritis patients with or without ulcerative colitis","volume":"15","author":"Ishikawa","year":"2024","journal-title":"Front Immunol"},{"key":"2026010105291313000_53.1.25.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2013.06.013"},{"key":"2026010105291313000_53.1.25.18","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1007\/s11926-024-01141-0","article-title":"How to monitor disease activity of axial spondyloarthritis in clinical practice","volume":"26","author":"Kumthekar","year":"2024","journal-title":"Curr Rheumatol Rep"},{"key":"2026010105291313000_53.1.25.19","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.2022-1272"},{"issue":"1","key":"2026010105291313000_53.1.25.20","doi-asserted-by":"crossref","first-page":"otz005","DOI":"10.1093\/crocol\/otz005","article-title":"The prevalence and characterization of axial spondyloarthritis among veterans with inflammatory bowel disease","volume":"360","author":"Salem","year":"2019","journal-title":"Crohn\u2019s & Colitis"},{"key":"2026010105291313000_53.1.25.21","doi-asserted-by":"publisher","DOI":"10.1080\/14737159.2023.2279611"},{"key":"2026010105291313000_53.1.25.22","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1093\/ecco-jcc\/jjz205","article-title":"Faecal calprotectin for the diagnosis of bowel inflammation in patients with rheumatological diseases: a systematic review","volume":"14","author":"Fauny","year":"2020","journal-title":"J Crohns Colitis"},{"key":"2026010105291313000_53.1.25.23","doi-asserted-by":"crossref","first-page":"jjaf062","DOI":"10.1093\/ecco-jcc\/jjaf062","article-title":"Anti-integrin \u03b1v\u03b26 IgG antibody as a diagnostic and prognostic marker in ulcerative colitis: a cross-sectional and longitudinal study defining a specific disease phenotype","volume":"19","author":"Pertsinidou","year":"2025","journal-title":"J Crohns Colitis"},{"key":"2026010105291313000_53.1.25.24","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.04.063"},{"key":"2026010105291313000_53.1.25.25","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223296"},{"key":"2026010105291313000_53.1.25.26","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/j.cgh.2024.10.005","article-title":"Anti-integrin \u03b1v\u03b26 autoantibodies are increased in primary sclerosing cholangitis patients with concomitant ibid and correlate with liver disease severity","volume":"23","author":"Bloemen","year":"2025","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.2024-1296","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T13:29:52Z","timestamp":1767274192000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.2024-1296"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,15]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,1]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.3899\/jrheum.2024-1296"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.2024-1296","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,15]]}}}